Leap Therapeutics to Present at Two Investor Conferences in April
March 29 2017 - 7:00AM
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company
developing targeted and immuno-oncology therapeutics, today
announced that Christopher K. Mirabelli, Ph.D., Chairman,
President, and Chief Executive Officer, will present corporate
overview presentations at the 16th Annual Needham Healthcare
Conference at the Westin New York Grand Central and the 24th Annual
BioCentury Future Leaders In the Biotech Industry Conference at the
Millennium Broadway Hotel in New York City. Presentation details
for both conferences are summarized below.
The presentation at the 16th Annual Needham
Healthcare Conference will be webcast live and may be accessed on
the Investors page of the company’s website at
www.investors.leaptx.com, where a replay of the event will also be
available for a limited time.
Leap Presentation Details:
16th Annual Needham Healthcare ConferenceDate:
April 5, 2017Time: 3:00 P.M. Eastern Time
24th Future Leaders in the Biotech Industry
ConferenceDate: April 7, 2017Time: 9:30 A.M. Eastern Time
About Leap TherapeuticsLeap
Therapeutics’ (NASDAQ:LPTX) most advanced clinical candidate,
DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1
(DKK1) protein. DKN-01 is in clinical trials in patients with
gastroesophageal cancer in combination with paclitaxel and in
patients with biliary tract cancers in combination with gemcitabine
and cisplatin. DKN-01 has demonstrated single agent activity in
non-small cell lung cancer patients. Leap’s second clinical
candidate, TRX518, is a novel, humanized GITR agonist monoclonal
antibody designed to enhance the immune system’s anti-tumor
response. For more information about Leap Therapeutics, visit
http://www.leaptx.com or our public filings with the SEC that are
available via EDGAR at http://www.sec.gov or via
http://www.investors.leaptx.com/.
FORWARD LOOKING STATEMENTS
Some of the statements in this release are
forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. These statements relate to
future events of Leap’s development of DKN-01, TRX518, and other
programs, future expectations, plans and prospects. Although Leap
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Leap has attempted
to identify forward looking statements by terminology including
‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’
‘‘plans,’’ ‘‘projects,’’ ‘‘intends,’’ ‘‘potential,’’ ‘‘may,’’
‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘approximately’’ or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors. Any forward looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
CONTACT
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Susan Kim
212-203-4433
susan@argotpartners.com
or
Heather Savelle
617-663-4863
heather@argotpartners.com
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jul 2023 to Jul 2024